following a full submission:
fluocinolone acetonide (Iluvien®) is accepted for use within NHSScotland.
Indication under review: prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
In a double-blind, phase III study in patients with recurrent non-infectious uveitis affecting the posterior segment of the eye, fluocinolone acetonide intravitreal implant reduced the number of recurrences of uveitis compared with sham injection.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- fluocinolone acetonide (Iluvien)
- SMC ID:
- SMC2260
- Indication:
For prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
- Pharmaceutical company
- Alimera Sciences
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2020